Used in the prevention of migraine headaches by targeting and inhibiting calcitonin gene-related peptide (CGRP), a molecule involved in migraine pathophysiology. This antibody binds to CGRP with high affinity, blocking its interaction with receptors and reducing neurogenic inflammation and pain signaling in the trigeminal system. It is administered intravenously, offering a rapid onset of action and long-lasting effects, typically dosed quarterly. Employed in clinical settings for patients with episodic or chronic migraines who may not respond adequately to conventional therapies. Also utilized as a reference standard in immunoassays and drug development research involving CGRP pathway inhibitors.